These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30881018)

  • 1. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance.
    Gao X; Chen H; Huang X; Li H; Liu Z; Bo X
    Onco Targets Ther; 2019; 12():1629-1640. PubMed ID: 30881018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor.
    Li J; Zhao J; Wang H; Li X; Liu A; Qin Q; Li B
    Onco Targets Ther; 2018; 11():5885-5894. PubMed ID: 30271172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma.
    Roth GS; Macek Jilkova Z; Zeybek Kuyucu A; Kurma K; Ahmad Pour ST; Abbadessa G; Yu Y; Busser B; Marche PN; Leroy V; Decaens T
    Mol Cancer Ther; 2017 Oct; 16(10):2157-2165. PubMed ID: 28566435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis.
    Li B; Feng F; Jia H; Jiang Q; Cao S; Wei L; Zhang Y; Lu J
    Food Funct; 2021 Mar; 12(6):2404-2417. PubMed ID: 33570057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells.
    Wu M; Zhao G; Zhuang X; Zhang T; Zhang C; Zhang W; Zhang Z
    Onco Targets Ther; 2018; 11():2945-2954. PubMed ID: 29849464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.
    Jilkova ZM; Kuyucu AZ; Kurma K; Ahmad Pour ST; Roth GS; Abbadessa G; Yu Y; Schwartz B; Sturm N; Marche PN; Hainaut P; Decaens T
    Oncotarget; 2018 Feb; 9(13):11145-11158. PubMed ID: 29541403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
    Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib.
    Chen Z; Jiang Z; Zhang W; He B
    Cancer Manag Res; 2018; 10():3057-3067. PubMed ID: 30214300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition.
    Hu B; Cheng JW; Hu JW; Li H; Ma XL; Tang WG; Sun YF; Guo W; Huang A; Zhou KQ; Gao PT; Cao Y; Qiu SJ; Zhou J; Fan J; Yang XR
    J Cancer; 2019; 10(17):3914-3925. PubMed ID: 31417635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
    Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
    Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
    Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
    J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma.
    Yang X; Xia W; Chen L; Wu CX; Zhang CC; Olson P; Wang XQ
    Oncotarget; 2018 Oct; 9(79):34996-35007. PubMed ID: 30405889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
    Lai YL; Wang KH; Hsieh HP; Yen WC
    J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
    Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
    Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
    Shao Z; Li Y; Dai W; Jia H; Zhang Y; Jiang Q; Chai Y; Li X; Sun H; Yang R; Cao Y; Feng F; Guo Y
    Pharmacol Res; 2018 Sep; 135():188-200. PubMed ID: 30114438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.